Could a wakefulness drug tame MS fatigue?

NCT ID NCT06170970

Recruiting now Symptom relief Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether solriamfetol (Sunosi), a drug used for sleepiness, can reduce fatigue in people with multiple sclerosis who also have excessive daytime sleepiness. About 46 participants will receive either the drug or a placebo for four weeks, then switch after a washout period. The study uses a smartphone app to track fatigue through typing patterns, aiming for more precise measurements.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Solriamfetol (Sunosi)
What this could lead to: If it works, this could offer a new treatment option for fatigue in people with multiple sclerosis who also have excessive daytime sleepiness.
What could go wrong: This is a small, early-phase trial (46 people) and may not show clear benefit. Fatigue is complex, and results may not apply to everyone with MS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disorders of Excessive Somnolence Fatigue multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS MULTIPLE SCLEROSIS FATIGUE

Contacts and locations

Locations

Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.